Boehringer Ingelheim India and Lupin announce strategic co-marketing agreement

Lupin to market Empagliflozin under the brand name Gibtulio in India


Boehringer Ingelheim and pharma major Lupin Limited announced another strategic alliance to co-market Empagliflozin, a novel sodium glucose co-transporter-2 (SGLT-2) inhibitor in India.

Boehringer Ingelheim and Lupin had earlier signed a partnership for Co-Marketing Linagliptin in October 2015. The inclusion of Empagliflozin is a significant addition to the partnership.

SGLT-2 Inhibitors are a novel class of drugs that were launched across the world in the last couple of years. According to the agreement, Lupin will market and sell Empagliflozin under a separate brand name Gibtulio which will be promoted by Lupin's specialty field force. Boehringer Ingelheim will continue to sell Empagliflozin under the brand name Jardiance through their existing sales force and network.

Gibtulio and Jardiance tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. They are available in 10 mg and 25 mg strength.

The Indian diabetes market is valued at INR 9,003 Crore, growing at 19.5% (IMS MAT July 2016). The market has been driven largely by the entry of newer drugs like DPP-4 Inhibitors over the last 6 years and the SGLT-2 Inhibitors are expected to outgrow & outpace the market faster than before.

Previous 1 Next

Leave a Reply Sign in

Notify me of follow-up comments via e-mail address

Post Comment

Survey Box

National Health Policy

Is National Health Policy 2017 helpful for patients?

Send this article by email